Onpode
Cover art for FDA grants first-ever Breakthrough Therapy status to Cu-64 SAR-bisPSMA for prostate cancer recurrence detection

FDA grants first-ever Breakthrough Therapy status to Cu-64 SAR-bisPSMA for prostate cancer recurrence detection

November 13, 2026 · 9 min

Eliza Ward & Brian Reed

Hey. You doing alright? Yeah, good. I've got — there's something in my inbox I want to make sure we get right before we start throwing numbers around. The Clarity Pharmaceuticals thing. That's the one. FDA just gave a Breakthrough Therapy designation — this week, around November 12th — to their imaging agent. Cu-64 SAR-bisPSMA.…

On November 12, 2026, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to Clarity Pharmaceuticals' Cu-64 SAR-bisPSMA, making it the first PSMA PET imaging agent ever to receive that designation. Clarity Pharmaceuticals is an Australian clinical-stage radiopharmaceutical company listed on the ASX under the ticker CU6.

0:009:09
Get the next episode on Health →

Follow it free — new episodes land in your feed.

Or make your own — any topic, in minutes

More Onpode episodes on Health →

About this episode

On November 12, 2026, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to Clarity Pharmaceuticals' Cu-64 SAR-bisPSMA, making it the first PSMA PET imaging agent ever to receive that designation. Clarity Pharmaceuticals is an Australian clinical-stage radiopharmaceutical company listed on the ASX under the ticker CU6.

Grounded in 11 sources
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer ↗ · pmc.ncbi.nlm.nih.gov
FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer | FDA ↗ · fda.gov
Clarity’s Cu-64 PSMA agent gets FDA breakthrough designation | AuntMinnie ↗ · auntminnie.com
First FDA Breakthrough Therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and I ↗ · claritypharmaceuticals.com
Clarity Pharmaceuticals' PSMA PET Agent Earns FDA Breakthrough Therapy Designation ↗ · diagnosticimaging.com
FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for Prostate Cancer PET Imaging: 78% Detection vs 36% in Trial | GSM Global ↗ · gsmglobalnews.com
Clarity Secures First FDA Breakthrough Therapy Designation for PSMA PET Imaging as Copper-64 Challenges Established Tracers — Nuclio Media ↗ · nuclionews.com
https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-64cu-sar-bispsma-for-psma-pet-in-biochemically ↗ · onclive.com
https://smallcaps.com.au/article/clarity-pharmaceuticals-granted-breakthrough-therapy-designation-for-prostate-cancer-copper-theranostic ↗ · smallcaps.com.au
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging ↗ · urologytimes.com
First FDA Breakthrough Therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer ↗ · prnewswire.com
Read transcript

Brian Reed: Hey. You doing alright?

Eliza Ward: Yeah, good. I've got — there's something in my inbox I want to make sure we get right before we start throwing numbers around.

Brian Reed: The Clarity Pharmaceuticals thing.

Eliza Ward: That's the one. FDA just gave a Breakthrough Therapy designation — this week, around November 12th — to their imaging agent. Cu-64 SAR-bisPSMA. First time that's happened for any PSMA PET imaging agent ever.

Brian Reed: And I want to slow down on what Breakthrough Therapy actually means here, because I think — hang on — the announcement language and the clinical reality are doing different work.

Eliza Ward: Yes. That is exactly the thing.

Brian Reed: So what's the drug actually for? Like, in plain terms — who gets this?

Eliza Ward: Men who've been treated for prostate cancer — surgery, radiation — and then their PSA starts creeping back up. That's called biochemical recurrence. The question is: where is the cancer? PSMA is a protein that prostate cancer cells overexpress, so this agent targets that. The imaging finds lesions the standard scans miss.

Brian Reed: So it's basically a tagged molecule that hunts for those cells and lights them up on the scan. Like — your body is the map, the tracer is the highlighter.

Eliza Ward: That's it. That's the whole thing. PSMA is overexpressed on prostate cancer cells, the agent binds to it, it shows up on the PET scan. One sentence.

Brian Reed: Right — but the part that doesn't fit is the headline. Because 'Breakthrough Therapy' sounds like the FDA said this works better. And that's... actually not what happened.

Eliza Ward: It really isn't. Breakthrough Therapy is a process designation. It means the FDA is willing to hold the drug's hand through review faster — more guidance, more back-and-forth. It doesn't — wait, the analogy is a faster lane at customs. You still have to clear customs. The lane just moves quicker.

Brian Reed: And it doesn't guarantee approval.

Eliza Ward: Correct. The designation was supported by Phase II Co-PSMA trial data, the COBRA Phase I/II data, some real-world evidence — all preliminary. The two registrational Phase III trials, AMPLIFY and CLARIFY, haven't reported topline data yet. Those are expected H1 2027.

Brian Reed: So right now, no patient outside a clinical trial can actually access Cu-64 SAR-bisPSMA. The designation is real, the drug is not on shelves.

Eliza Ward: Exactly. And the other thing — the market isn't empty. Ga-68 PSMA-11 got FDA approval in December 2020. Pylarify is also approved. So 'first Breakthrough Therapy designation in PSMA PET imaging' is accurate, but it's the first designation, not the first agent. Clarity Pharmaceuticals is entering a space that already has competition.

Brian Reed: That's the reframe. It's not a new modality arriving — it's a potentially better version trying to prove itself against things that are already in the clinic.

Eliza Ward: And that 'better version' framing is exactly where the circulating take goes wrong. Because the number doing all the work right now — 78% versus 36% — that's real. The Co-PSMA trial actually produced that. But the way it's getting used is, I think, outrunning what a Phase II can actually prove.

Brian Reed: Name the take. What's the bad version that's out there?

Eliza Ward: 'Cu-64 SAR-bisPSMA doubles detection. It's a game-changer.' That's — wait, that's the frame. And the number is real, but the frame is doing too much.

Brian Reed: Right, so the Co-PSMA trial enrolled patients at a median PSA of 0.43 nanograms per milliliter. That's — I mean, picture the actual patient. Guy's maybe sixty-two, three years out from prostatectomy, PSA just nudged above 0.4. That is a low-burden biochemical recurrence case. And that is exactly the window where Ga-68 PSMA-11 is already known to underperform. So you're not testing on a neutral population — you're testing on the population where the existing agent already has the most trouble.

Eliza Ward: Which could mean the 42-point gap shrinks in a less selected population. We don't know.

Brian Reed: And even if it doesn't — detecting more lesions in that guy, does it actually change what his urologist does next? The Phase II doesn't answer that.

Eliza Ward: No. And the COBRA trial data was also in the Breakthrough application, alongside real-world evidence — so it's not like they leaned on one study. But all of it is preliminary. None of it shows improved survival. None of it shows the detection advantage translates to a different treatment decision.

Brian Reed: Better map, same destination.

Eliza Ward: Until AMPLIFY and CLARIFY report — H1 2027 is the number to watch. And honestly, the distribution piece, what it means if Cu-64 actually clears that Phase III gate — that's a whole other layer we haven't touched yet.

Brian Reed: That distribution piece is — let me think about what that actually means in practice. Because a PET center in, say, rural Montana doesn't have a cyclotron sitting in the basement. Ga-68's half-life is so short they'd basically need one on-site or close enough to run same-day delivery. That's why PSMA PET hasn't reached those places.

Eliza Ward: Cu-64 runs about 12.7 hours. Which sounds like a chemistry footnote until you do the math — you can actually image up to 30 hours post-injection. That's enough time to manufacture it centrally, put it on a truck or a cargo flight, and have it arrive still viable.

Brian Reed: So a radiopharmacy in, I don't know, Denver produces a batch on a Tuesday morning — it ships out and a clinic in Billings actually uses it that afternoon.

Eliza Ward: That's the scenario. Ga-68 PSMA-11 can't do that. The half-life is too short — you're not shipping it across a time zone.

Brian Reed: Hang on — so the access gap isn't really about whether the agent works. It's about whether the physics let you move it at all.

Eliza Ward: Right. And — wait, the clinical advantage and the infrastructure advantage are two separate arguments. Even if AMPLIFY and CLARIFY come back and say the detection edge is real, that still doesn't automatically solve distribution. Reimbursement, institutional formularies — Breakthrough Therapy doesn't touch any of that.

Brian Reed: And those two trials — AMPLIFY is in biochemical recurrence patients, CLARIFY is prior to definitive therapy — both completed recruitment. So the data exists, we just don't have it. H1 2027 is what Clarity has said, not the FDA.

Eliza Ward: That's the number to hold. Clarity's stated expectation, not a confirmed milestone.

Brian Reed: So the actual question for a community hospital administrator right now isn't 'is this better?' It's 'will insurance pay for it, and can I actually receive a shipment?' And neither AMPLIFY nor the Breakthrough designation answers that.

Eliza Ward: And that's — wait, that's actually where I land on all of this. The Breakthrough Therapy designation tells us the FDA looked at Co-PSMA, looked at COBRA, looked at the real-world evidence, and said the early signal is worth accelerating. That part is settled. What it doesn't tell us is whether finding that extra 42 percentage points of lesions changes what a doctor does, or whether the man lives longer because of it. Those are different questions and AMPLIFY and CLARIFY are the only things that answer them.

Brian Reed: And both trials — recruitment done, data not here yet. So we're in this window where the designation is real, the Phase II number is real, and the actual clinical value is still... genuinely open.

Eliza Ward: H1 2027. That's the number.

Brian Reed: And when that reads out — I mean, what are we actually hoping to see? Not just a detection rate. That's already the Phase II story. For it to matter, AMPLIFY needs to show that the urologist in that clinic made a different call because of what the Cu-64 SAR-bisPSMA scan found. Treatment decisions. And ideally, something downstream of that.

Eliza Ward: Outcomes. Yeah. That's the loop that hasn't closed. And honestly — we don't know if it will. That's not hedging, that's just where the evidence stops right now.